Top line decelerating.
+10.6% YoY versus +23.6% prior. 3y CAGR +18.0%.
+10.6%We use cookies
MainRatios uses cookies for essential site functions. With your consent, we also use analytics cookies including session replay sampling (PostHog, Google Analytics) and advertising cookies (Google AdSense). You can reject non-essential cookies, including the "sale" or sharing of personal information under CCPA, and you may withdraw consent at any time (GDPR). See our Privacy Policy for details.
Healthcare · Market Cap: $22.8B
Live price unavailable
Fundamentals as of 2026-03-31
All analysis on this page is for educational purposes only and does not constitute financial advice. Fair values are model-based estimates. Always do your own research.
The Question
2 of 3 legendary models say BUY UTHR — but Charlie Munger disagrees.
What would legendary investors pay for UTHR?
These figures are not quotes or opinions from Buffett, Graham, Lynch or the other investors. They are our own estimates, computed by applying the intrinsic-value formulas each investor is known for to this company’s financials.
For educational purposes only. Not a recommendation to buy or sell securities.
Yes — United Therapeutics Corporation's 21.8% ROE ranks above the S&P 500 median, and D/E 0.14 stays within healthy bounds.
Financial story
Yes — United Therapeutics Corporation's 21.8% ROE shows strong capital efficiency, and its 0.14 debt-to-equity stays within healthy bounds.
Bottom line: UTHR is rated BUY by all 3 legendary models, 29% below avg fair value $771, but earns a A sector grade (77/100) in Healthcare. Whether the premium is justified depends on which lens you trust. Drill into the valuation breakdown and sector ranking for the full picture.
UTHR is in the Healthcare sector. Sector ranking and peer comparison are in the sector tab.
2 of 3 legendary investor models rate UTHR a BUY. Fair value estimates and full investor breakdown are in the valuation tab.
Average fair value across qualifying models: $771. See the per-investor fair-value table in the valuation tab.
UTHR trades at 20.9x earnings. Sector context and per-investor signals are in the valuation tab.
UTHR and LH differ on P/E, ROE, and revenue growth. See the full UTHR vs LH compare matrix.
Buffett, Lynch, and Munger evaluate UTHR against their respective frameworks. Per-model fair value and reasoning are in the
How does UTHR compare?
See exactly where UTHR ranks
Sign in to unlock the full sector ranking — free.
Sign in to see the rankingUTHR ranks in the top 23% of Healthcare, scoring 77/100 (A) — strongest in profitability, weakest in value.